Evidence map›Paper›PMID 36927526›Full record

ArticleBMC psychiatry2023

A national population-based study of cannabis use and correlates among U.S. veterans prescribed opioids in primary care.

Tauheed Zaman, Dawn M Bravata, Amy L Byers, Erin E Krebs, Samuel J Leonard, Friedhelm Sandbrink, Wylie Barker, Salomeh Keyhani

Open access · goldFull text read
In one paragraph

Article in BMC psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Cannabinoids and the Gastrointestinal Tract.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Tauheed ZamanAddiction Recovery and Treatments Services, San Francisco VA Health Care System, San Francisco, CA, USA. tauheed.zaman@ucsf.edu.ORCID 0000-0002-4425-6417
Dawn M BravataRichard L. Roudebush VA Medical Center, Indianapolis, IN, USA.
Amy L ByersDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.
Erin E KrebsCenter for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA.
Samuel J LeonardNorthern California Institute for Research and Education, San Francisco, CA, USA.
Friedhelm SandbrinkNational Pain Management, Opioid Safety and Prescription Drug Monitoring Program, Veterans Health Administration, Washington, DC, USA.
Wylie BarkerNorthern California Institute for Research and Education, San Francisco, CA, USA.
Salomeh KeyhaniDepartment of Medicine, University of California, San Francisco, CA, USA.
Northern California Institute for Research and Education · USSan Francisco VA Medical Center · USGeorge Washington University · USMinneapolis VA Health Care System · USRichard L. Roudebush VA Medical Center · USUniversity of California, San Francisco · US

Funding

Risks of Cannabis Use Among Veterans on Long-term Opioid TherapyI01HX002737 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI KEYHANI, SALOMEH · 2020 to 2024
–
HSRD VA I01 HX002737HSRD VA SDR 02-237
6 · The paper itself

Abstract

backgroundCannabis is marketed as a treatment for pain. There is limited data on the prevalence of cannabis use and its correlates among Veterans prescribed opioids.

objectiveTo examine the prevalence and correlates of cannabis use among Veterans prescribed opioids.

designCross-sectional study.

participantsVeterans with a urine drug test (UDT) from Primary Care 2014-2018, in 50 states, Washington, D.C., and Puerto Rico. A total of 1,182,779 patients were identified with an opioid prescription within 90 days prior to UDT. MAIN MEASURES: Annual prevalence of cannabis positive UDT by state. We used multivariable logistic regression to assess associations of demographic factors, mental health conditions, substance use disorders, and pain diagnoses with cannabis positive UDT.

resultsAnnual prevalence of cannabis positive UDT ranged from 8.5% to 9.7% during the study period, and in 2018 was 18.15% in Washington, D.C. and 10 states with legalized medical and recreational cannabis, 6.1% in Puerto Rico and 25 states with legalized medical cannabis, and 4.5% in non-legal states. Younger age, male sex, being unmarried, and marginal housing were associated with use (p < 0.001). Post-traumatic stress disorder (adjusted odds ratio [AOR] 1.17; 95% confidence interval [CI] 1.13-1.22, p < 0.001), opioid use disorder (AOR 1.14; CI 1.07-1.22, p < 0.001), alcohol use disorder or positive AUDIT-C (AOR 1.34; 95% CI 1.28-1.39, p < 0.001), smoking (AOR 2.58; 95% CI 2.49-2.66, p < 0.001), and other drug use disorders (AOR 1.15; 95% CI 1.03-1.29, p = 0.02) were associated with cannabis use. Positive UDT for amphetamines AOR 1.41; 95% CI 1.26-1.58, p < 0.001), benzodiazepines (AOR 1.41; 95% CI 1.31-1.51, p < 0.001) and cocaine (AOR 2.04; 95% CI 1.75-2.36, p < 0.001) were associated with cannabis positive UDT.

conclusionsCannabis use among Veterans prescribed opioids varied by state and by legalization status. Veterans with PTSD and substance use disorders were more likely to have cannabis positive UDT. Opioid-prescribed Veterans using cannabis may benefit from screening for these conditions, referral to treatment, and attention to opioid safety.

Indexed as

CannabisHallucinogensVeteransAnalgesics, OpioidCross-Sectional StudiesHumansMalePainPrimary Health CareUnited StatesAnalgesics, OpioidHallucinogensCannabisOpiatesOpioid therapyVeterans

Identifiers

PMID36927526
PMCPMC10021973
OpenAlexW4327544918

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read54
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.